PFE Stock Recent News

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday.

CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.

Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.

Five years ago, the eyes of the world were on Pfizer (PFE -2.00%). The big drugmaker was racing to develop a COVID-19 vaccine with its partner, BioNTech (BNTX -1.41%).

As a newish investor, I used to get my head turned all the time by the next exciting growth stock. Growth stocks can be great, and more than a few of them have helped my portfolio grow well.

PFE and CAG are two standout 7%-yielders that have relatively safe payouts. Headwinds facing both firms are tremendous, but there's already so much negativity priced in at these depths.

Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

You'd think that companies with long, successful track records and market caps in the hundreds of billions of dollars would be viewed as relatively formidable. However, that's not always the case.